163 related articles for article (PubMed ID: 34822853)
1. Inhibition of ocular neovascularization by novel anti-angiogenic compound.
Gau D; Vignaud L; Francoeur P; Koes D; Guillonneau X; Roy P
Exp Eye Res; 2021 Dec; 213():108861. PubMed ID: 34822853
[TBL] [Abstract][Full Text] [Related]
2. Apatinib, an Inhibitor of Vascular Endothelial Growth Factor Receptor 2, Suppresses Pathologic Ocular Neovascularization in Mice.
Kim KL; Suh W
Invest Ophthalmol Vis Sci; 2017 Jul; 58(9):3592-3599. PubMed ID: 28715845
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic effect of dasatinib in murine models of oxygen-induced retinopathy and laser-induced choroidal neovascularization.
Seo S; Suh W
Mol Vis; 2017; 23():823-831. PubMed ID: 29225458
[TBL] [Abstract][Full Text] [Related]
4. Nrf2 Activator RS9 Suppresses Pathological Ocular Angiogenesis and Hyperpermeability.
Nakamura S; Noguchi T; Inoue Y; Sakurai S; Nishinaka A; Hida Y; Masuda T; Nakagami Y; Horai N; Tsusaki H; Hara H; Shimazawa M
Invest Ophthalmol Vis Sci; 2019 May; 60(6):1943-1952. PubMed ID: 31050722
[TBL] [Abstract][Full Text] [Related]
5. ATN-161 as an Integrin α5β1 Antagonist Depresses Ocular Neovascularization by Promoting New Vascular Endothelial Cell Apoptosis.
Sui A; Zhong Y; Demetriades AM; Shen J; Su T; Yao Y; Gao Y; Zhu Y; Shen X; Xie B
Med Sci Monit; 2018 Aug; 24():5860-5873. PubMed ID: 30133427
[TBL] [Abstract][Full Text] [Related]
6. A peptide derived from type 1 thrombospondin repeat-containing protein WISP-1 inhibits corneal and choroidal neovascularization.
Cano Mdel V; Karagiannis ED; Soliman M; Bakir B; Zhuang W; Popel AS; Gehlbach PL
Invest Ophthalmol Vis Sci; 2009 Aug; 50(8):3840-5. PubMed ID: 19279315
[TBL] [Abstract][Full Text] [Related]
7. microRNA-181a inhibits ocular neovascularization by interfering with vascular endothelial growth factor expression.
Yang C; Tahiri H; Cai C; Gu M; Gagnon C; Hardy P
Cardiovasc Ther; 2018 Jun; 36(3):e12329. PubMed ID: 29608244
[TBL] [Abstract][Full Text] [Related]
8. Targeting retinal and choroid neovascularization using the small molecule inhibitor carboxyamidotriazole.
Afzal A; Caballero S; Palii SS; Jurczyk S; Pardue M; Geroski D; Edelhauser H; Hochhaus G; Kim M; Franklin A; Shapiro G; Grant MB
Brain Res Bull; 2010 Feb; 81(2-3):320-6. PubMed ID: 19679174
[TBL] [Abstract][Full Text] [Related]
9. Secretogranin III as a novel target for the therapy of choroidal neovascularization.
LeBlanc ME; Wang W; Ji Y; Tian H; Liu D; Zhang X; Li W
Exp Eye Res; 2019 Apr; 181():120-126. PubMed ID: 30633921
[TBL] [Abstract][Full Text] [Related]
10. Pathogenic role and therapeutic potential of pleiotrophin in mouse models of ocular vascular disease.
Wang W; LeBlanc ME; Chen X; Chen P; Ji Y; Brewer M; Tian H; Spring SR; Webster KA; Li W
Angiogenesis; 2017 Nov; 20(4):479-492. PubMed ID: 28447229
[TBL] [Abstract][Full Text] [Related]
11. Brivanib, a multitargeted small-molecule tyrosine kinase inhibitor, suppresses laser-induced CNV in a mouse model of neovascular AMD.
Li L; Zhu M; Wu W; Qin B; Gu J; Tu Y; Chen J; Liu D; Shi Y; Liu X; Sang A; Ding D
J Cell Physiol; 2020 Feb; 235(2):1259-1273. PubMed ID: 31270802
[TBL] [Abstract][Full Text] [Related]
12. An efficacy analysis of anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to multifocal choroiditis and comparison with wet age-related macular degeneration.
Feng L; Hu JH; Chen J; Xie X
J Zhejiang Univ Sci B; 2018 Apr.; 19(4):327-332. PubMed ID: 29616508
[TBL] [Abstract][Full Text] [Related]
13. Repurposing antimalarial aminoquinolines and related compounds for treatment of retinal neovascularization.
McAnally D; Siddiquee K; Gomaa A; Szabo A; Vasile S; Maloney PR; Divlianska DB; Peddibhotla S; Morfa CJ; Hershberger P; Falter R; Williamson R; Terry DB; Farjo R; Pinkerton AB; Qi X; Quigley J; Boulton ME; Grant MB; Smith LH
PLoS One; 2018; 13(9):e0202436. PubMed ID: 30208056
[TBL] [Abstract][Full Text] [Related]
14. Ocular neovascularization: Implication of endogenous angiogenic inhibitors and potential therapy.
Zhang SX; Ma JX
Prog Retin Eye Res; 2007 Jan; 26(1):1-37. PubMed ID: 17074526
[TBL] [Abstract][Full Text] [Related]
15. Anti-angiogenic effects of a mutant endostatin: a new prospect for treating retinal and choroidal neovascularization.
Bai Y; Zhao M; Zhang C; Li S; Qi Y; Wang B; Huang L; Li X
PLoS One; 2014; 9(11):e112448. PubMed ID: 25380141
[TBL] [Abstract][Full Text] [Related]
16. Nonpeptide somatostatin receptor agonists specifically target ocular neovascularization via the somatostatin type 2 receptor.
Palii SS; Afzal A; Shaw LC; Pan H; Caballero S; Miller RC; Jurczyk S; Reubi JC; Tan Y; Hochhaus G; Edelhauser H; Geroski D; Shapiro G; Grant MB
Invest Ophthalmol Vis Sci; 2008 Nov; 49(11):5094-102. PubMed ID: 18599562
[TBL] [Abstract][Full Text] [Related]
17. Both Autocrine Signaling and Paracrine Signaling of HB-EGF Enhance Ocular Neovascularization.
Inoue Y; Shimazawa M; Nakamura S; Takata S; Hashimoto Y; Izawa H; Masuda T; Tsuruma K; Sakaue T; Nakayama H; Higashiyama S; Hara H
Arterioscler Thromb Vasc Biol; 2018 Jan; 38(1):174-185. PubMed ID: 29191924
[TBL] [Abstract][Full Text] [Related]
18. The potent small molecule integrin antagonist THR-687 is a promising next-generation therapy for retinal vascular disorders.
Hu TT; Vanhove M; Porcu M; Van Hove I; Van Bergen T; Jonckx B; Barbeaux P; Vermassen E; Feyen JHM
Exp Eye Res; 2019 Mar; 180():43-52. PubMed ID: 30472075
[TBL] [Abstract][Full Text] [Related]
19. Lenalidomide, an anti-tumor drug, regulates retinal endothelial cell function: Implication for treating ocular neovascular disorder.
Dong LF; Yao J; Wang XQ; Shan K; Yang H; Yan B; Jiang Q
Biochem Biophys Res Commun; 2015 Oct; 465(4):678-84. PubMed ID: 26255966
[TBL] [Abstract][Full Text] [Related]
20. Preclinical Efficacy and Safety of VEGF-Grab, a Novel Anti-VEGF Drug, and Its Comparison to Aflibercept.
Hong HK; Park YJ; Kim DK; Ryoo NK; Ko YJ; Park KH; Kim HM; Woo SJ
Invest Ophthalmol Vis Sci; 2020 Nov; 61(13):22. PubMed ID: 33196778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
